Gilead Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel O'Day
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Jan 22, 1992
- CIK
- 0000882095
- Website
- gilead.com
- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Avidity Partners Management LP Purchases Shares of 20,000 Gilead Sciences, Inc. $GILD
Axiom Investment Management LLC Makes New $677,000 Investment in Gilead Sciences, Inc. $GILD
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Gilead: Buy The Distortion Before Q2 Clears It Up
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Bank of Nova Scotia Decreases Stock Position in Gilead Sciences, Inc. $GILD
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
Acumen Wealth Advisors LLC Has $886,000 Stock Holdings in Gilead Sciences, Inc. $GILD
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
Andra AP fonden Has $31.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD
Dimensional Fund Advisors LP Lowers Stock Holdings in Gilead Sciences, Inc. $GILD